浙江医药股份有限公司 2016 年第一季度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2016 年第一季度报告 1 / 18 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 浙江医药股份有限公司 2016 年第一季度报告 3 / 18 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人 李春波、主管会计工作负责人王明达及会计机构负责人（会计主管人员）冯丹音 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 浙江医药股份有限公司 2016 年第一季度报告 一、 重要提示 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | ...

2015 年第三季度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2015 年第三季度报告 1 / 22 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 11 | 2015 年第三季度报告 一、 重要提示 2.1 主要财务数据 3 / 22 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 8,087,881,123.76 7,869,425,252.91 2.78 归属于上市公司 股东的净资产 6,555,984,124.09 6,538,251,188.72 0.27 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的 现金流量净额 -39,298,809.15 257,822,708.83 -115.24 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （%） 营业收入 3,38 ...

Financial Performance - The company's operating revenue for the first half of 2015 was CNY 2,145,640,125.40, a decrease of 15.67% compared to CNY 2,544,312,973.61 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2015 was CNY 134,860,418.72, down 36.26% from CNY 211,565,259.51 in the previous year[19]. - The net cash flow from operating activities was negative CNY 27,619,183.04, a decline of 121.01% compared to CNY 131,433,154.58 in the same period last year[19]. - Basic earnings per share for the first half of 2015 were CNY 0.144, a decrease of 36.28% from CNY 0.226 in the same period last year[20]. - The weighted average return on net assets was 2.04%, down 1.20 percentage points from 3.24% in the previous year[20]. - The company reported a net profit excluding non-recurring gains and losses of negative CNY 68,359,134.25, compared to a profit of CNY 216,082,805.26 in the same period last year, a decline of 131.64%[19]. - The diluted earnings per share were also CNY 0.144, reflecting the same decrease of 36.28% compared to the previous year[20]. - The company achieved operating revenue of 21.46 billion RMB in the first half of 2015, completing 44.70% of the annual target of 48 billion RMB[38]. - The net profit for the first half of 2015 was CNY 186,531,510.69, an increase of 31.8% compared to CNY 141,529,631.55 in the same period last year[94]. - The total revenue from operating activities was CNY 2,332,473,892.03, down 12.7% from CNY 2,671,542,521.32 in the previous year[97]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 8,312,049,859.08, an increase of 5.62% from CNY 7,869,425,252.91 at the end of the previous year[19]. - The total liabilities reached CNY 1,685,148,572.92, compared to CNY 1,307,726,234.85 at the beginning of the year, reflecting a rise of 28.8%[86]. - Owner's equity totaled CNY 6,626,901,286.16, up from CNY 6,561,699,018.06, showing an increase of 1%[86]. - The company's total assets at the end of the period were CNY 6,515,217,133.73, up from CNY 6,350,303,560.99 at the beginning of the year[107]. - The company's total liabilities decreased to CNY 1,135,198,504.19 from CNY 1,171,737,998.63 at the beginning of the year[107]. Revenue Breakdown - Sales revenue for the main product, Vitamin E, was CNY 483,920,000, down 44.15% year-on-year due to continued low market demand[28]. - The sales revenue for Vitamin D3 increased by 100.80% year-on-year, driven by higher average prices compared to the previous year[28]. - The company achieved a sales revenue of CNY 917,081,400 in its pharmaceutical commercial business, despite significant price declines due to drug bidding and secondary negotiations[30]. - The sales revenue of animal nutrition products was 549,075,898.62 RMB, a decrease of 31.15% year-on-year[40]. - The sales revenue of human nutrition products was 294,865,216.63 RMB, down 36.20% compared to the previous year[40]. - The pharmaceutical manufacturing segment saw a revenue increase of 11.92% to 379,187,847.99 RMB[40]. Cash Flow - The net cash flow from investing activities was -127,907,897.50 RMB, an improvement of 57.06% year-on-year[34]. - The net cash flow from financing activities was 253,269,819.47 RMB, an increase of 415.11% compared to the previous year[34]. - The cash flow from operating activities showed a net outflow of CNY 27,619,183.04, a significant decline from a net inflow of CNY 131,433,154.58 in the previous year[97]. - The company generated CNY 361,136,000.00 from financing activities, a significant increase from CNY 61,528,000.00 in the same period last year[98]. - The investment activities resulted in a net cash outflow of CNY 127,907,897.50, compared to a larger outflow of CNY 297,868,708.74 in the previous year[97]. Shareholder Information - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[4]. - The company distributed a cash dividend of CNY 0.6 per 10 shares, totaling CNY 56,166,480.00, based on a total share capital of 93,610,800 shares as of December 31, 2014[55]. - The total number of shareholders at the end of the reporting period was 59,727[73]. - The largest shareholder, Xin Chang Changxin Investment Development Co., Ltd., held 22.14% of the shares[73]. - The company has committed to avoiding competition with its controlling shareholders and actual controllers[66]. Research and Development - R&D expenditure increased by 21.44% to 71,987,488.65 RMB due to the increase in R&D projects[34]. - The company has established a strong R&D, production, and marketing integrated management system, enhancing its core competitiveness[46]. Corporate Governance - The company experienced a change in its board of directors, with multiple resignations due to term expirations, including the general manager and several independent directors[79]. - The new board of directors includes key appointments such as Lü Yonghui as president and Zhang Zheng as a director, indicating a shift in leadership[80]. - The company held four board meetings, four supervisory meetings, and one shareholders' meeting during the reporting period[68]. Investments and Projects - The company has invested CNY 299,272,000.00 in the Vancomycin sterile powder injection project, which is currently 65% complete, with a total investment of CNY 179,746,795.86 to date[53]. - The Vancomycin project is expected to generate annual sales revenue of USD 50 million once operational[54]. - The company sold 3,136,852 shares of Bank of Communications, generating an investment income of CNY 17,226,079.01, and sold 12,970,000 shares of Zhejiang Xianju Pharmaceutical, earning CNY 214,376,200.00[49]. Compliance and Regulations - The company has not disclosed any significant litigation or arbitration matters during the reporting period[59]. - The financial statements are prepared based on the assumption of going concern, with no significant doubts regarding the company's ability to continue operations for the next 12 months[114]. - The company adheres to the accounting standards, ensuring that its financial reports accurately reflect its financial position and operating results[115]. Accounting Policies - The company recognizes revenue from the sale of goods when the main risks and rewards of ownership have been transferred to the buyer, and the revenue amount can be reliably measured[158]. - The company assesses long-term asset impairment annually, regardless of whether there are indications of impairment, particularly for goodwill and intangible assets with indefinite useful lives[151]. - The company has established accounting policies for employee compensation, including short-term and post-employment benefits, ensuring liabilities are recognized in the period services are provided[153][154].

2014 年年度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2014 年年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经天健会计师事务所(特殊普通合伙)审计，2014 年度归属于母公司股东的净利润为 169,739,354.50 元，母公司净利润为 52,705,989.61 元。按《公司章程》规定，以 2014 年度实 现的母公司净利润 52,705,989.61 元为基数，提取 10%法定盈余公积金 5,270,598.96 元，提取 5% 的任意盈余公积金 2,635,299.48 元后，加上母公司期初未分配利润 3,381,096,070.95 元，期末 母公司可供股东分配利润为 3,425,896,162.12 元。公司拟以 2014 年 12 月 31 日公司总股本 93,610.80 万股为基数，向全体股东每 10 股派送现金红利 0.6 元（含税），计派送现金红利 56,166,480.00 元，剩余未分配利润结转下一年度。 六、 前瞻性陈述的风险声明 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 ...

2015 年第一季度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2015 年第一季度报告 1 / 19 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2015 年第一季度报告 一、 重要提示 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 8,197,702,498.57 | 7,869,425,252.91 | 4.17 | | | 归属于上市公司股东 | 6,604,786,509.90 | 6,538,251,188.72 | 1.02 | | | 的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的现金 | -89,732,995.5 ...

2014 年第三季度报告 浙江医药股份有限公司 2014 年第三季度报告 1 / 25 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 11 | 2014 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李春波、主管会计工作负责人李春风及会计机构负责人（会计主管人员）梁林美 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 7,854,703 ...

浙江医药股份有限公司 600216 2014 年半年度报告 浙江医药股份有限公司 2014 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 白明辉 | 工作原因 | 罗林 | 三、 公司半年度财务报告未经审计。 四、 公司负责人李春波、主管会计工作负责人李春风及会计机构负责人（会计主管人员） 梁林美声明：保证本半年度报告中财务报告的真实、准确、完整。 五、 是否存在被控股股东及其关联方非经营性占用资金情况？ 否 浙江医药股份有限公司 2014 年半年度报告 第一节 释义 一、 释义 3 在本报告书中，除非文义另有所指，下列词语具有如下含义： 常用词语释义 浙江医药、公司 指 浙江医药股份有限公司 新昌制药厂 指 浙江医药股份有限公司新昌制药厂 维生素厂 指 浙江医药股份有限公司维生素厂 昌海生物、浙江昌 ...

1.2 公司全体董事出席董事会审议季度报告。 1.3 浙江医药股份有限公司 600216 2014 年第一季度报告 | P | 4 | | --- | --- | | | A | | 一、 | 重要提示 2 | | --- | --- | | 二、 | 公司主要财务数据和股东变化 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 600216 浙江医药股份有限公司 2014 年第一季度报告 一、重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 | 公司负责人姓名 | 李春波 | | --- | --- | | 主管会计工作负责人姓名 | 李春风 | | 会计机构负责人（会计主管人员）姓名 | 梁林美 | 公司负责人李春波、主管会计工作负责人李春风及会计机构负责人（会计主管人员）梁林美 保证季度报告中财务报表的真实、准确、完整。 1.4 公司第一季度报告中的财务报表未经审计。 2 600216 浙江医药股份有限公司 2014 年第一季度报告 二、公司主要财务数据和股东变化 2 ...

浙江医药股份有限公司 2013 年年度报告 浙江医药股份有限公司 600216 2013 年年度报告 1 浙江医药股份有限公司 2013 年年度报告 重要提示 一、 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人李春波、主管会计工作负责人李春风及会计机构负责人（会计主管人员） 梁林美声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案： 浙江医药股份有限公司 2013 年年度报告 | 目 录 | | --- | 经天健会计师事务所(特殊普通合伙)审计，2013 年度归属于母公司股东的净利润为 452,095,249.90 元，母公司净利润为 457,473,352.86 元。按公司章程规定，以 2013 年度实现 的母公司净利润 457,473,352.86 元为基数，提取 10%法定盈余公积金 45,747,335.29 ...